Navigation Links
SRI Researchers Validate Preclinical Effectiveness of Tuberculosis Drug Target that Could Shorten Treatment Time
Date:11/29/2011

MENLO PARK, Calif., Nov. 29, 2011 /PRNewswire/ -- In research at SRI International, scientists evaluating new drug targets against tuberculosis (TB) recently validated the preclinical effectiveness of a target that could rapidly eliminate infections and potentially shorten treatment time. The new drug target is a protein called DNA gyrase B, found in bacteria that cause TB infections.

DNA gyrase is an enzyme consisting of two subunits: gyrase A and gyrase B. Although gyrase A is often the target of antibiotics, such as ciprofloxacin, there currently is no antibiotic on the market that targets gyrase B. In laboratory experiments, SRI researchers found that by targeting gyrase B, TB bacteria are killed whether they are replicating or dormant. Further studies will be conducted toward the development of a TB drug against gyrase B.  

"One of the greatest needs in infectious disease treatment is a drug that allows a shorter length of treatment," said Peter Madrid, Ph.D., program director in the Center for Infectious Disease and Biodefense Research, SRI Biosciences Division. "Though our program is still in the preclinical phase of research, with a number of years of required testing ahead, our goal is to develop a drug that will improve the treatment process for TB patients."

TB patients currently undergo treatment for six months and take a combination of at least four different drugs. There are often challenges to treatment effectiveness because of the long treatment time, including low patient treatment compliance and high rates of drug resistance. Tuberculosis that is resistant to multiple drugs takes even longer to treat, usually 18 to 24 months.

Research results are presented in the November 2011 Journal of Antimicrobial Chemotherapy in a paper titled "Evaluation of Gyrase B as a Drug Target in Mycobacterium tuberculosis."

The project described was supported by Award Numbers R56AI090817 and U01AI082070 from the National Institute of Allergy And Infectious Diseases. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute of Allergy and Infectious Diseases or the National Institutes of Health.

About SRI's Biosciences Division
SRI's Biosciences Division carries out basic research, drug discovery, and drug development, and provides contract services. SRI has all of the resources necessary to take R&D from Idea to IND®—from initial discovery to the start of human clinical trials—and specializes in cancer, immunology and inflammation, infectious disease, and neuroscience. SRI's product pipeline has yielded marketed drugs, therapeutics currently in clinical trials, and additional programs in earlier stages. In its CRO business, SRI has helped government and other clients and partners advance well over 100 drugs into patient testing. SRI is also working to create the next generation of technologies in areas such as diagnostics, drug delivery, medical devices, and systems biology.

About SRI International
Silicon Valley-based SRI International, a nonprofit research and development organization, performs sponsored R&D for governments, businesses, and foundations. SRI brings its innovations to the marketplace through technology licensing, new products, and spin-off ventures. Commemorating its 65th anniversary in 2011, SRI is known for world-changing innovations in computing, health and pharmaceuticals, chemistry and materials, sensing, energy, education, national defense, and more.


'/>"/>
SOURCE SRI International
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. University Hospitals Case Medical Center Researchers Search for Mysteries of Dystonia With Advanced Brain Imaging
2. SANYO Offers Researchers Energy-Efficient, Space-Saving Solutions for Biological Sample Preservation
3. "Scientific Oktoberfest" Draws the Worldwide Leading Researchers in the Field of Chemical Biology to Munich
4. CVS Caremark, Harvard and Brigham and Womens Researchers Say Medicare Donut Hole Can Lead to a Decrease in Medication Adherence
5. Researchers Find RapidArc® Radiotherapy from Varian Medical Systems Can Quickly and Accurately Deliver Total Marrow Irradiation (TMI) Treatments for Patients with Blood Cancers
6. Researchers Present Key Findings Comparing PEM to MRI for Identification of Contralateral Breast Cancer at the National Consortium of Breast Centers (NCBC) Conference
7. Cannabis Science Forms Military Advisory Board That Will Be Comprised of Distinguished Military Leaders, Military Health Care Providers, Researchers and Educators Headed Up by Lieutenant Colonel, U.S. Army (Ret) Kevin Sullivan
8. Chemistry Researchers Create New Tool to Visualize Bloodstains
9. UPDATED: Elsevier Online Opinion Survey Reveals Researchers Ready to Push Scientific Search and Discovery to the Next Level
10. CulGenex™ by Hardy Diagnostics Assists Medical Researchers!
11. Researchers Use Nanoparticles as Destructive Beacons to Zap Tumors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2016)... , May 6, 2016  Hill-Rom Holdings, Inc. (NYSE: ... of Directors declared a fiscal year 2016 third quarter ... percent increase over the amount paid a year ago. ... record as of the close of business on June 10, ...    Hill-Rom is a leading global medical technology ...
(Date:5/5/2016)... International plc (NASDAQ: ENDP ) (TSX: ENL) today ... president of Allergan, Inc. and current CEO of Chase Pharmaceuticals ... TPG Capital, to its Board of Directors. The appointments are ... recently embarked on a search for new Board members who ... and Todd are experienced leaders, and we are extremely pleased ...
(Date:5/5/2016)... Research and Markets has announced the addition ... EU Markets"  report to their offering.  ,     (Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO ... the current Positron Emission Tomography (PET) scanner and cyclotron install ... includes France , Germany ... and the United Kingdom . Along ...
Breaking Medicine Technology:
(Date:5/6/2016)... ... 06, 2016 , ... The Price Agency in Birmingham, AL ... assist the people of their local community. The agency pledges to select a ... Their desire is to bring awareness to important local causes with fundraising and ...
(Date:5/6/2016)... ... May 06, 2016 , ... The joy associated with Mother’s Day is mixed with ... neonatal intensive care units (NICUs) across the country. For the first time ever, the ... honor these women who spend their Mother’s Day beside a crib surrounded by lifesaving equipment ...
(Date:5/6/2016)... ... ... US Sports Camps has collaborated with State Rugby Organization (SRO), Rugby Oregon, ... Employing world-class rugby figures, including former Team USA players and college coaches, this program ... match play, fitness and more. , “US Sports Camps is honored to be working ...
(Date:5/6/2016)... ... May 06, 2016 , ... Bluvault ( Bluvault Inc. ... offering for global clients of Coupa ( Coupa Software ) and other Cloud ... is a key component in the suite of innovative implementation services offered by ...
(Date:5/6/2016)... ... May 06, 2016 , ... ... reduce fat areas around the body, is the most popular among body sculpting ... released make perfect sense to cosmetic surgeon Dr. Richard Buckley, medical director of ...
Breaking Medicine News(10 mins):